Abstract

Objective
To determine whether the expression of IL17A and CD21L genes in inflamed rheumatoid synovia is associated with the neogenesis of ectopic lymphoid follicle-like structures (ELS), and if this aids the stratification of rheumatoid inflammation and thereby distinguishes patients with rheumatoid arthritis that might be responsive to specific targeted biologic therapies.

Methods
Expression of IL17A and CD21L genes was assessed by RT-PCR, qRT-PCR and dPCR in synovia from 54 patients with rheumatoid arthritis. A subset of synovia (n = 30) was assessed by immunohistology for the presence of CD20+ B-lymphocytes and size of CD20+ B-lymphocyte aggregates as indicated by maximum radial cell count. The molecular profiles of six IL17A+/CD21L+ and six IL17A−/CD21L− synovia were determined by complementary DNA microarray analysis.

Results
By RT-PCR, 26% of synovia expressed IL17A and 52% expressed CD21L. This provided the basis for distinguishing four subgroups of rheumatoid synovia: IL17A+/CD21L+ (18.5% of synovia), IL17A+/CD21L− (7.5%), IL17A−/CD21L+ (33.3%) and IL17A−/CD21L− (40.7%). While the subgroups did not predict clinical outcome measures, comparisons between the synovial subgroups revealed the IL17A+/CD21L+ subgroup had significantly larger CD20+ B-lymphocyte aggregates (P = 0.007) and a gene expression profile skewed toward B-cell- and antibody-mediated immunity. In contrast, genes associated with bone and cartilage remodelling were prominent in IL17A−/CD21L− synovia.
Conclusions

Rheumatoid synovia can be subdivided on the basis of IL17A and CD21L gene expression. Ensuing molecular subgroups do not predict clinical outcome for patients but highlight high inflammation and the predominance of B-lymphocyte mediated mechanisms operating in IL17A+/CD21L+ synovia. This may provide a rationale for more refined therapeutic selection due to the distinct molecular profiles associated with IL17A+/CD21L+ and IL17A-/CD21L+ rheumatoid synovia.

Introduction

Rheumatoid arthritis (RA) is a chronic inflammatory disease that principally affects the synovial lining of joints. The associated synovial inflammation is heterogeneous encompassing histological features that distinguish fibroid, myeloid or lymphoid pathotypes, and associated molecular signatures [1, 2]. Where the inflammation is dominated by lymphocytes, cellular organisation covers a spectrum from a diffuse, less organised infiltrate, through increasing formation of lymphoid aggregates to more highly organised ectopic lymphoid follicle-like structures (ELS) with germinal centres [2, 3].

Mechanisms that underlie lymphocyte aggregation and ELS formation in rheumatoid synovium closely follow those involved in the formation of secondary lymphoid tissue during development. A source of lymphotoxin-β (LTβ) is crucial, which in inflamed synovium includes group 3 innate lymphoid cells (ILC3s) or lymphoid tissue inducer (LTI) cells, and probably also infiltrating B- and T-lymphocytes. LTβ activates pre-follicular dendritic cells (pre-FDCs; see below) and NFκB-inducing kinase-positive (NIK+) endothelial cells [4, 5] to produce chemokines and upregulate adhesion molecules. Key chemokines, including CXCL13 play crucial roles in the entry of B cells into the inflamed tissues that may further amplify the inflammatory process [6].

Mature FDCs are also a requisite for ELS neogenesis, particularly for the progression towards ELS with germinal centres (GC+ ELS), facilitating the production of high-affinity antibodies [7]. FDCs originate from platelet-derived growth factor-β-positive (PDGFRβ+)-perivascular pre-FDCs, which initially also express FDC-M1 (alternatively named milk fat globule epidermal growth factor 8; MFGE8) [4]. Mature FDCs are characterised by expression of the long isoform of the CD21 gene (CD21L) [8]. The formation of GC+ ELS in rheumatoid synovia favours the affinity maturation of B cells [9] and is thought to support the local production of the anti-cyclic citrullinated auto-antibodies associated with RA [7], although the true function of these synovial ELS is not clear. Known also as lymphoid follicles, ELS are present in 44–58% of rheumatoid synovial membranes with ~21–24% having GCs and CD21L+ FDC networks [10, 11]. There are associations between the presence of GC+ ELS in synovium, presence of rheumatoid factor (RF) and greater disease severity [11]. Such features demarcate rheumatoid inflammation that is more obviously B-lymphocyte driven.

As well as the key chemokines LTβ, CXCL13 and CXCL12, a number of cytokines also make well-defined contributions to the patterns of synovial inflammation seen in RA. Interleukin (IL)-17A is produced in a varied percentage of rheumatoid joint synovia [12, 13], with evidence suggesting that the presence of IL-17A is both predictive of disease progression in RA [12] and contributes to the inflammation by synergising with the actions of other key inflammatory mediators such as IL-1β, IL-6 and TNF-α [14, 15]. Meta-analysis of randomised
controlled clinical trials for the treatment of RA with biological agents that neutralise IL-17A further emphasise the importance of the IL-17A pathway to RA [16].

Interleukin-17A is produced by a variety of cells including CD4⁺ Th17 cells, CD8⁺ T cells, natural killer cells, γδ-T cells, mast cells, and double-negative CD3⁺ T cells. In rheumatoid synovium, Th17 cells are found in lymphocyte-enriched areas [13] and in the vicinity of IL-23 producing monocytes [17] implicating the IL-17A/IL-23 axis in ELS formation [18, 19]. A key feature of Th17 cells is their plasticity, with different states achieved in humans distinguished by co-expression of the signature cytokine, IL-17A (and IL17F), alongside other cytokines like IL-10 or IFNγ [20–23]. In turn, the various combinations of cytokines impart distinct cellular effector functions. Consequently, Th17 cells function within a spectrum that spans from regulatory to more pathogenic, but not necessarily dependent on IL-17A production.

A key objective in the management of RA is the application of personalised therapy for control of joint synovial inflammation. In this study, we consider the expression of the CD21L and IL17A genes in rheumatoid synovium, reflecting the combined presence of FDCs and contribution from IL-17A to the synovial inflammation. We sought to determine whether expression of IL17A and CD21L in synovial tissue is associated with a distinct phase(s) of ELS neogenesis, and if the associated gene expression profile could aid the stratification of rheumatoid inflammation.

Materials and methods

Patients, synovial tissues and classification

All participants in this study gave written informed consent. The study was approved by the Multi-region Health and Disability Ethics committee (New Zealand), Ref No. MEC/06/02/003. Clinical data was obtained from medical record review.

Fifty-four synovia were obtained during joint replacement surgery from 45 patients with RA, as defined by the American Rheumatism Association 1987 classification criteria [24]. Multiple synovia were obtained from 8 patients, either at the same time or after periods of 5–67 months. From 3–6 resected pieces (≤0.4 cm³) of each synovium were stored frozen in liquid nitrogen, with each piece randomly assigned for various analyses of gene expression, as required. An additional 2–4 resected pieces were snap frozen embedded in tissue-tek for immuno-histology.

Total RNA (TRNA) was extracted from ~50–100 mg of synovial tissue and reverse transcribed as previously described [17]. Using the following sense and antisense primers (respectively) for IL17A: 5’-ATG ACT CCT GGG AAG ACC TCA TTG-3’ and 5’-TTA GGC CAC ATG GTG GAC AAT CGG-3’; and CD21L: 5’-GTG GAT TTA CTT TGA AGG GCA-3 and 5’-GGC ATG TTT CTT CAC ACC G-3’, the expression of IL17A and CD21L genes was assessed by PCR and agarose gel-based detection. On this basis synovia were classified as positive or negative for IL17A and CD21L expression and assigned to one of four groups.

Assays of gene expression

Levels of gene expression were further quantitated by standard real-time PCR (qRT-PCR) or by digital PCR (dPCR) assays using commercially available IL17A (Hs00174383_m1), GAPDH (Hs99999905_m1) Taqman assays (Applied Biosystems) and a custom-designed CD21L Taqman assay based on the reporter sequence within CD21L: 5’-ACGGTGTGAAGA AACAT-3’ (Applied Biosystems). For qRT-PCR, the analysis of each gene was performed in triplicate, with comparisons relative to tonsil standard RNA (ng) and the results for individual samples expressed as the mean for each gene relative to the mean of GAPDH RNA. Digital-PCR
analysis was performed as previously described [25], using Quantstudio 3D digital PCR 20K chip kits and utilising a single chip per sample. Digital results are expressed as absolute values (i.e. non-normalised) for the number of gene specific RNA molecules per ng of RNA.

**Synovial immunohistology**

For assessment of lymphoid aggregation 7μm cryostat sections from replicate synovial tissue samples were stained with Gill’s haematoxylin 3 and 0.5% alcoholic eosin. Samples were de-identified and the size of lymphoid aggregates quantified by maximum radial cell count (MRCC) as previously described [26].

Consecutive sections were immunohistochemically stained as previously described [17] for the expression CD21L (anti-CD21L; Santa Cruz Biotechnology, Inc.) or T- and B-lymphocytes (anti-CD3 and anti-CD20 respectively; DakoCytomation) using mouse monoclonal antibodies. Non-specific antibody binding was blocked by incubating sections with 2.5% normal rabbit serum (Sigma). Primary antibodies were detected with rabbit anti-mouse IgG-conjugated horse radish peroxidase (HRP; DakoCytomation) visualised with chromogenic substrate (DAB, 1 mg/ml; DAKO Corporation), and nuclei counter-stained with Gill’s haematoxylin 3. Photomicrographs were taken using an Olympus BX50 microscope fitted with Spot RT digital camera and software (Diagnostic Instruments).

Values are expressed as group median and the interquartile range (IQR) unless otherwise stated. Differences in gene expression levels, MRCC and aggregate numbers among synovial subgroups were determined using the Kruskal-Wallis test, followed by paired comparisons with Dunn’s Multiple Comparison test. Multivariate analysis was performed for CD21L/IL17A subtype associations with disease characteristics, aggregate and gene expression using generalised estimating equation population-averaged model analyses (Log Binomial and Modified Poisson Regression with exchangeable correlations) in MedCalc v11.4.2.0. All other statistical analyses were performed using Prism 4 for Windows v4.03 (GraphPad Software). Values of $P < 0.05$ were considered statistically significant.

**Microarray analysis**

For microarray analysis a subset of 12 rheumatoid synovia, classified on the basis of gene expression as $IL17A^+$/CD21L$^+$ (n = 6) or $IL17A^-$/CD21L$^-$ (n = 6), obtained from 10 patients were identified. Two $IL17A^+$/CD21L$^+$ synovia (P1-1 and P1-2) were obtained from one patient, 14-months apart. A second patient provided one $IL17A^+$/CD21L$^+$ synovium (P4-1) and 5-months later, one $IL17A^-$/CD21L$^-$ synovium (P4-2).

The purity and integrity of extracted synovial TRNA were established by capillary electrophoresis (Bioanalyser; Agilent). Sample hybridisation and microarray data analysis was performed by the Otago Genomics Facility (University of Otago, Dunedin). Briefly, 5 μg total RNA was amplified and labelled using the MessageAmp™ Premier RNA Amplification Kit (Ambion), according to the manufacturer’s specifications. Ten μg of biotinylated complementary RNA was then fragmented and hybridised at 45˚C for 16 h to GeneChip Human Genome U133 Plus 2.0 arrays containing ~38,500 characterised genes (~54,000 probe sets; Affymetrix).

To compare gene expression profiles from the different arrays, data was analysed with the Affymetrix Expression Console version 1.1 (MAS 5.0) using Affymetrix default analysis settings and with Robust Multiarray Average (RMA) as the normalisation method [27]. Raw and normalised data (GEO accession: GSE38064) are available online at http://www.ncbi.nlm.nih.gov/geo/). Differences in gene expression were calculated as fold-changes by comparing the mean of normalised values for the six $IL17A^+$/CD21L$^+$ synovia with the mean of normalised values for the six $IL17A^-$/CD21L$^-$ synovia, for each probe set. Significance was determined by
generating a t-statistic and p-value for each probe set using Bioconductor Software AffyImGUI [28]. A two-sided $P < 0.05$ was considered statistically significant.

To identify genes with heterogeneous or related expression profiles, hierarchical cluster analysis was applied. Normalised signals for each probe set with significantly different expression were median-centred and analysed by complete-linkage hierarchical clustering of genes and arrays using Gene Cluster and visualised in TreeView (online at http://rana.lbl.gov/EisenSoftware.htm) [29].

To determine the pathways and biological processes represented by the genes with significantly different levels of expression in $\text{IL17A}^+ \text{CD21L}^+$ synovia compared to $\text{IL17A}^- \text{CD21L}^-$ synovia, gene ontology analysis was performed using the Protein ANalysis Through Evolutionary Relationships database (PANTHER; online at http://pantherdb.org) [30]. Statistically significant over-representation of genes involved in various pathways and processes was determined by comparing the genes with significantly different expression against a reference $\text{Homo sapiens}$ NCBI gene list using the binomial statistic [31]. Statistical significance was considered as $P < 0.05$.

**Results**

**Patients and synovial tissues**

Our patient cohort comprised 45 patients with RA providing 54 synovia. Mean ± SE age of this cohort was 61 ± 1.7 years, with mean ± SE disease duration 9.8 ± 1.4 years. Sixteen (36%) patients were male, 31 (69%) had nodules and 42 (93%) had radiographic erosions. Multiple synovia were obtained from 8 of 45 patients, with 4 patients each providing 2 separate synovia at different times, 5–67 months apart. A further 4 patients, each provided two separate synovial samples from two different joints at the same time; one of these patients provided an additional synovium ~12 months later.

**IL17A and CD21L gene expression distinguishes subgroups of rheumatoid synovia**

Rheumatoid synovia ($n = 54$) were assessed for $\text{IL17A}$ and $\text{CD21L}$ gene expression using PCR and agarose gel-based detection, thereby classifying synovia within one of four possible subgroups ($\text{IL17A}^+ \text{CD21L}^+$, $\text{IL17A}^+ \text{CD21L}^-$, $\text{IL17A}^- \text{CD21L}^+$, or $\text{IL17A}^- \text{CD21L}^-$). Applying this approach, we found that 14 (26%) of 54 rheumatoid synovia, had detectable $\text{IL17A}$ gene expression and 28 (52%) $\text{CD21L}$ expression. Considering the four possibilities for expression of these two genes, 10 of 54 synovia (19%) were identified as $\text{IL17A}^+ \text{CD21L}^+$, and 22 synovia (41%), identified as $\text{IL17A}^- \text{CD21L}^-$. Synovia with $\text{IL17A}$ expression alone were comparatively rare (7% in this cohort) compared to those with $\text{CD21L}$ expression alone (33%). Demographics of patients contributing the $\text{IL17A}$ and $\text{CD21L}$ classified synovia are shown in Table 1.

We sought verification of a PCR-based approach to classifying synovia from the quantitation of transcript by real-time qRT-PCR. In all $\text{IL17A}^+$ synovia (regardless of $\text{CD21L}$ expression), median expression level of $\text{IL17A}$ was 0.077 ng (IQR = 0.04–0.18 ng); In $\text{IL17A}^-$ synovia, no quantifiable transcript was detected. In all $\text{CD21L}^+$ synovia (regardless of $\text{IL17A}$ expression), median expression of $\text{CD21L}$ was 0.011 ng (IQR = 0.006–0.041 ng). In addition, low levels of $\text{CD21L}$ transcript (median expression 0.0015 ng; IQR = 0.0004–0.0028 ng) were detected by real-time qRT-PCR in 23/26 (88%) $\text{CD21L}^-$ synovia. The lack of overlap in the IQR for transcripts in $\text{IL17A}^+$ vs $\text{IL17A}^-$ synovia or $\text{CD21L}^+$ vs $\text{CD21L}^-$ synovia indicated the use of PCR and gel-based assays to distinguish $\text{IL17A}/\text{CD21L}$ synovial subgroups. Median expression for both $\text{IL17A}$ and $\text{CD21L}$ genes, amongst the four possible synovial subgroups, is summarised in
Table 1. Patient demographic and clinical data for synovia classified by the expression of **IL17A** and **CD21L**.

|                     | IL17A⁺/CD21L⁺ | IL17A⁺/CD21L⁻ | IL17A⁻/CD21L⁺ | IL17A⁻/CD21L⁻ |
|---------------------|---------------|---------------|---------------|---------------|
| No. of synovia      | 10 (19%)      | 4 (7%)        | 18 (33%)      | 22 (41%)      |
| No. of Patientsᵃ    | 9             | 4             | 17            | 20            |
| Age, median (IQR)   | 62.5 (36.5–68.5) | 66.5 (58.5–70.5) | 65.5 (46.0–69.5) | 64 (54.5–70.0) |
| % Female            | 56%           | 100%          | 59%           | 90%           |
| RF Positive         | 8             | 4             | 17            | 19            |
| ACPA Positive       | 6/8ᵇ          | 3/4           | 12/15         | 12/13         |
| Subcutaneous nodules present | 6 | 3 | 10 | 12 |
| Radiographic erosions present | 8 | 4 | 17 | 17 |
| Disease duration, median (IQR) years | 10.5 (4.8–23.0) | 8.0 (5.3–14.6) | 16.1 (8.0–26.0) | 16.5 (8.0–24.0) |
| ESR, median (IQR) mm/hr | 27.5 (19.5–40.0)ᶜ | 36.5 (N/A) | 25.0 (13.5–30.0) | 26.5 (15.0–44.5) |
| CRP, median (IQR) mg/dL | 12.0 (4.0–16.0)ᶜ | 31.5 (13.5–56.5) | 7.0 (4.0–18.5) | 19.5 (4.0–14.0) |
| Taking DMARDs       | 9             | 4             | 17            | 17            |

ᵃPatient cohort (n = 45) included 8 patients providing multiple (2–3) synovia. Following tissue classification, 5 patients contributed to more than one classification group.

ᵇACPA data was only available for 37/45 patients with 84% of 37 patients, ACPA⁺. ACPA positive data show ACPA⁺ patients per number of patients tested within each classification group.

ᶜESR and CRP data was only available for 33/45 patients (73%).

The IQR could not be determined for subgroups of low samples size, denoted by N/A.

Abbreviations: RF, rheumatoid factor; ACPA, anti-citrullinated peptide antibodies; ESR, erythrocyte sedimentation rate; CRP, C-reactive protein; DMARDs, disease modifying anti-rheumatic drugs. No patients were receiving biologic therapy.

https://doi.org/10.1371/journal.pone.0202135.t001

Table 2. These data establish significant differences in **IL17A** and **CD21L** expression, particularly between the **IL17A⁺/CD21L⁺** and **IL17A⁻/CD21L⁻** synovia.

We reasoned that absolute (i.e. non-normalised) measures of **IL17A** and **CD21L** expression, obtained using dPCR, would be compatible with PCR and gel-based detection, and might provide universally comparable measures for distinguishing between synovial subgroups. We compared absolute measures of **IL17A** and **CD21L** expression between **IL17A⁺/CD21L⁻** and **IL17A⁻/CD21L⁺** synovia (Fig 1). The more sensitive dPCR assays reveal few synovia with a complete lack of gene expression but data highlight the skew towards higher absolute measures of **IL17A** and **CD21L** expression in **IL17A⁺/CD21L⁺** synovia. Our data suggest absolute measures of expression ≥ 0.25 copies/ng RNA for **IL17A** (Odds ratio (OR) = 2.4) and ≥ 0.7 copies/ng RNA for **CD21L** (OR = 11), as guidelines for distinguishing “positive” from “negative” expression.

**Combined IL17A and CD21L gene expression is associated with increased synovial lymphocyte aggregation**

Individually, IL-17A and CD21L have been implicated in lymphoid neogenesis [19, 32]. Therefore, we sought evidence for an association between combined **IL17A** and **CD21L** gene expression and lymphoid organisation in rheumatoid synovia. A subset of synovia (n = 30/54 synovia; 26 patients) comprising 27% **IL17A⁺/CD21L⁺**, 10% **IL17A⁻/CD21L⁺**, 23% **IL17A⁻/CD21L⁻** and 40% **IL17A⁺/CD21L⁻** were examined histologically. Prominent inflammation and more obvious organisation of infiltrating lymphocytes into aggregates was a feature of
IL17A+/CD21L+ synovia (data not shown). In comparison, IL17A−/CD21L− synovia had comparatively fewer inflammatory cells and demonstrated a largely diffuse inflammatory infiltrate. A mixed pattern was observed in IL17A+/CD21L− and IL17A−/CD21L+ synovia that included some areas of diffuse infiltration and, particularly in perivascular locations, some organisation of inflammatory cells into aggregates.

We next assessed the relationship between expression of IL17A and CD21L and size of aggregates containing CD20+ B-lymphocytes. As indicated by MRCC, the median size of aggregates containing CD20+ B-lymphocytes was significantly different between the synovial subgroups (P = 0.007; Table 3). Post-hoc analysis identified significantly larger, but not more, aggregates containing CD20+ B-lymphocytes within IL17A+/CD21L+ synovia, compared to those in IL17A−/CD21L+ synovia and IL17A+/CD21L− synovia (P < 0.05; Table 3). Together these results suggest that the combined expression of CD21L and IL17A genes is associated

### Table 2. Quantitative gene expression in synovial tissue subgroups defined by the expression of IL17A and CD21L.

| Synovial Subgroup | Number (%) | IL17A expression | CD21L expression |
|-------------------|------------|------------------|-----------------|
| IL17A+/CD21L+     | 10 (18.5)  | 0.095 (0.073–0.176)* | 0.011 (0.003–0.077) |
| IL17A+/CD21L−     | 4 (7.5)    | 0.086 (0.033–0.713) | 0.005 (0.002–0.008) |
| IL17A−/CD21L+     | 18 (33.3)  | 0 (0–0.030)†‡   | 0.005 (0.002–0.023) |
| IL17A−/CD21L−     | 22 (40.7)  | 0 (0–0)†§      | 0.002 (0–0.006)* |
| P-value           |            | <0.0001*        | 0.030            |

Synovial tissues were classified into subgroups based on PCR-based gel assays for IL17A and/or CD21L expression.

*Values from qRT-PCR are presented as median expression in ng RNA relative to GAPDH, with IQR shown in parenthesis.

*Comparison among all IL17A/CD21L subgroups was performed by Kruskal-Wallis test, followed by paired comparisons with Dunn’s Multiple Comparison test.

*P<0.05,

*P<0.001 compared to IL17A+/CD21L+ synovia.

*P<0.05,

*P<0.01 compared to IL17A+/CD21L− synovia.

https://doi.org/10.1371/journal.pone.0202135.t002

***Fig 1. Absolute measures of synovial IL17A or CD21L gene expression.*** Synovia were originally classified into IL17A+/CD21L− (n = 12) or IL17A+/CD21L+ (n = 10) subgroups. Digital PCR was used to establish absolute measures of (A) IL17A expression or (B) CD21L expression in each of these subgroups. Outliers within each subgroup are shown as individual dots (●).

https://doi.org/10.1371/journal.pone.0202135.g001
with the presence of larger aggregates containing CD20⁺ B-lymphocytes in rheumatoid synovia. Notably the larger aggregates showed segregation of CD20⁺ B- and CD3⁺ T-lymphocytes into distinct regions (Fig 2).

**Combined IL17A and CD21L expression is not associated with clinical outcomes**

We assessed whether the combined expression of IL17A and CD21L genes was associated with standard clinical features and outcomes for RA. We compared disease characteristics, including age at onset, disease duration, and presence of erosions and subcutaneous nodules; measures of erythrocyte sedimentation rate (ESR), serum C-reactive protein (CRP), rheumatoid factor (RF) and anti-citrullinated peptide antibody (ACPA); measures of disease severity including van der Heijde Sharp score [33], number of previous joint surgeries; measures of disease impact including change in HAQ score, number of joint injections and hospital admissions per year; as well as number of disease modifying anti-rheumatic medications used since diagnosis. There was no significant difference in any of these variables between patients separated according to CD21L/IL17A synovial subgroup classification (data not shown).

Multi-variate analysis showed no association between the size of aggregates containing CD20⁺ B-lymphocytes and disease outcome, reflected by Sharp scores or as Sharp scores per year(s) of disease duration.

**Distinctive molecular profiles are associated with IL17A and CD21L expression in rheumatoid synovia**

While the IL17A/CD21L synovial subsets did not associate with clinical outcomes we considered that expression of the two genes may be associated with distinct molecular profiles. We anticipated such a distinction might provide clinically relevant insight into the heterogeneity of RA and potentially aid therapeutic selection.

Gene expression profiling of six IL17A⁺/CD21L⁺ and six IL17A⁻/CD21L⁻ synovia identified 3,092 transcripts with significantly different expression levels. Of these 1,433 transcripts were up-regulated in IL17A⁺/CD21L⁺ synovia and 1,659 in IL17A⁻/CD21L⁻ synovia. Hierarchical cluster analysis of the molecular profiles grouped the synovia into their corresponding IL17A⁺/CD21L⁺ and IL17A⁻/CD21L⁻ subgroups (Fig 3). The IL17A⁺/CD21L⁺ synovia show greater variation in their molecular profiles, compared to IL17A⁻/CD21L⁻ synovia (Fig 3). Two separate synovia from the same patient, obtained 14 months apart and both originally classified as

| Synovial Subgroup | MRCC (Cells) | Number (Aggregates) |
|-------------------|-------------|---------------------|
| IL17A⁺/CD21L⁺     | 7.5 (5.5–13.5)ᵃ | 3 (0.5–6.5) |
| IL17A⁺/CD21L⁻     | 5 (4–6) | 2 (N/A) |
| IL17A⁻/CD21L⁺     | 5 (0–7)ᵇ | 1 (0–2) |
| IL17A⁻/CD21L⁻     | 5 (3–7)ᵇ | 1 (0–3.5) |
| P-value           | 0.007ᵇ    | 0.54 |

ᵃValues are presented as median cells or aggregates, as appropriate, with IQR shown in parenthesis.
ᵇComparison among all IL17A/CD21L synovial subgroups was performed by Kruskal-Wallis test, followed by paired comparisons with Dunn’s Multiple Comparison test.

ᵇP < 0.05, compared to IL17A⁺/CD21L⁺ synovia. The IQR could not be determined for subgroups of low sample size, denoted by N/A.

https://doi.org/10.1371/journal.pone.0202135.t003
IL17A+/CD21L+, subsequently clustered with other IL17A+/CD21L+ synovia. In addition, two separate synovia from a second patient, which originally classified into different IL17A/CD21L subgroups, clustered appropriately; the IL17A+/CD21L+ synovium was obtained five months before the IL17A+/CD21L+ synovium (Fig 3). Thus, the gene expression profiles of synovia from the same IL17A+CD21L+ subgroup are similar between different patients. Moreover, the gene expression profiles are different between synovia of different IL17A/CD21L subgroups obtained from the same patient.

High inflammatory activity in IL17A+/CD21L+ synovial molecular profiles

Gene ontology analysis was performed to further characterise the genes up-regulated in IL17A+/CD21L+ or IL17A-/CD21L- synovia. Using the PANTHER database (Thomas, 2003),
Fig 3. Hierarchical cluster analysis of rheumatoid synovia. Shown are synovia ordered by hierarchical clustering of 3,092 transcripts with significant differential expression between IL17A+/CD21L+ (black) and IL17A-/CD21L- (blue) synovial subgroups. Paired synovia P1-1 and P1-2 are from one individual at the same time, and paired synovia P4-1 and P4-2 from another individual, 5 months apart. The matrix shows genes with significantly different expression in rows relative to the individual synovia samples in columns. Red indicates higher than median expression (black) and green lower than median expression across all assessed tissues. Coloured vertical bars indicate clusters of differentially expressed genes classified by PANTHER as "Immunity and defense", and "Developmental processes".

https://doi.org/10.1371/journal.pone.0202135.g003
this analysis incorporated 1,222 (85.3%) of the 1,433 genes significantly up-regulated in \( \text{IL17A}^+ / \text{CD21L}^+ \) synovia and 1,451 (87.5%) of the 1,659 genes significantly up-regulated in \( \text{IL17A}^- / \text{CD21L}^- \) synovia.

Genes up-regulated in \( \text{IL17A}^+ / \text{CD21L}^+ \) were significantly over-represented in 57 categories of biological processes. Of these the most significant was “Immunity and defence” \( (P = 2.31 \times 10^{-11}) \). Within this category are a number of well-defined processes that were also significantly over-represented by genes with up-regulated expression in \( \text{IL17A}^+ / \text{CD21L}^+ \) synovia (Fig 3).

These include “B-cell- and antibody-mediated immune processes” with associated genes that are specifically involved in B-cell receptor (BCR) formation and expression (e.g. \( \text{IGHM}, \text{IGK}, \text{IGL}, \text{CD19}, \text{CD79A}, \text{CD79B} \)), BCR signal modulation and transduction (e.g. \( \text{BLNK}, \text{PLCG2}, \text{VAV-2}, \text{MAPK1}, \text{MAPK14}, \text{FCRL5} \)) and immunoglobulin class-switching from IgM (e.g. \( \text{IGHA}, \text{IGHD}, \text{IGHG} \)). In addition, genes associated with lymphocyte co-stimulation (e.g. \( \text{ICOSLG}, \text{CTLA-4}, \text{SLAMF3}, \text{SLAMF7} \)) and antigen presentation (e.g. \( \text{HLA-DOA}, \text{HLA-DOB}, \text{HLA-C} \)) were up-regulated in \( \text{IL17A}^+ / \text{CD21L}^+ \) synovia. These results indicate that B-lymphocytes and other antigen-presenting cells are present and that there is a substantial B-lymphocyte focused, immune component to the inflammation associated with \( \text{IL17A}^+ / \text{CD21L}^+ \) synovia. Interestingly, amongst the significantly under-represented biological processes from genes up-regulated in \( \text{IL17A}^+ / \text{CD21L}^+ \) synovia were “protein biosynthesis” \( (P = 9.87 \times 10^{-04}) \) and “mitosis” \( (P = 0.032) \)."
featured suppressor of cytokine signalling 7 (SOCS7), which inhibits the expression of IL-23 and the Th17 cell transcription factor, retinoid-related orphan receptor-C (RORC) [34], potentially contributing to the absence of IL17A expression in IL17A+/CD21L− synovia.

Links between B-lymphocyte aggregation and RGS13 expression

Finally, from microarray data, we sought evidence to explain the mechanism by which IL-17A and CD21L+ FDCs might contribute to the greater B-lymphocyte aggregation found in IL17A+/CD21L+ synovia. We considered genes associated with B-lymphocyte survival, co-stimulation and trafficking for separate analysis, including IL23A, TLR9A, BAFF, APRIL, RGS13, RGS16 and SIPA-1.

Microarray data indicated greater expression of IL23A, TLR9A, and RGS13 in IL17A+/CD21L+ synovia, when compared to IL17A−/CD21L+ synovia (Fig 4). These patterns of expression were confirmed by qRT-PCR, alongside significantly greater expression of BAFF, in IL17A+/CD21L+ synovia (Fig 4). There was no significant difference in RGS16 expression between synovial subtypes, but generally greater RGS16 expression (by ~10-fold) compared to RGS13. Similarly, APRIL expression was not significantly different between synovial subgroups. While APRIL and BAFF were expressed at comparable levels in IL17A+/CD21L+ synovia, significantly less BAFF expression, (by ~4-fold) was evident in IL17A−/CD21L+ synovia. While not significant, there was a trend for more SIPA1 transcript in IL17A+/CD21L− synovia (Fig 4).
Fig 4. Gene expression in synovial subtypes. Expression of selected genes associated with B-lymphocyte survival, co-stimulation and trafficking was compared. Microarray data (A) shows genes in rows relative to the individual synovial samples with higher (red) or lower (green) median expression across all tissues indicated. Array data is clustered within IL-17A+/CD21L+ (black) or IL17A-/CD21L- (blue) synovial subtypes showing greater expression (asterisks) of IL-23A, TLR9A, and RGS13 in IL-17A+/CD21L+ synovia, when compared to IL-17A-/CD21L- synovia. (B) Significantly greater expression of IL23A, TLR9A, RGS13 and BAFF expression in IL-17A+/CD21L+ synovia was confirmed by qRT-PCR.

https://doi.org/10.1371/journal.pone.0202135.g004
Discussion

Variability of the inflammation involving synovial tissue is a feature of RA. Histologically, distinct types of synovial pathology are recognised, predominantly involving either monocyte/macrophages (myeloid pathotype), or lymphocytes (lymphoid pathotype), or alternatively with fibroblast involvement and comparatively less inflammation (fibroid pathotype) [35]. A key objective has been to utilise these differences in synovial inflammation to divide RA into clinically meaningful subgroups that might represent variation in the underlying pathology for individual patients. On this basis, it may be possible to predict disease outcome and/or determine optimal choice of therapy. Critical to this objective are approaches that accurately reflect the heterogeneity of inflammation and that distinguish different patterns of active immune-mediated disease.

In this study, we utilised expression of the \( CD21L \) gene as a molecular biomarker for FDCs which, when combined with measures of \( IL17A \) expression, formed the basis for classifying synovial tissues. Further we utilised digital-PCR to establish absolute measures of \( CD21L \) and \( IL17A \) gene expression that provide guidelines for international comparisons between tissues, regardless of assay.

Previous studies have identified FDCs amongst requisites for the development of the ectopic GC\(^+\) ELS observed in rheumatoid synovia [32]. Expression of \( CD21L \) reflecting these cells was measurable in most (~94%) synovia by qRT-PCR and dPCR, but generally at low levels. In practice, we found that application of guidelines for absolute measures of gene expression or the comparatively less sensitive agarose gel-based PCR assays introduce a practical working threshold that discriminate synovia as \( CD21L^+ \) or \( CD21^- \). Synovia with the higher levels of \( CD21L \) expression featured well-organised ELS, with well-demarcated B- and T-cell segregation. However, GC\(^+\) ELS, and histologically distinguishable FDCs, were rare among our synovial samples. This high prevalence but low levels of \( CD21L \) gene expression and the relative paucity of GC\(^+\) ELS suggest that synovial \( CD21L \) expression reflects a tissue microenvironment capable, through the presence of FDCs (or their precursors), of developing ELS, rather than one where ELS are actually present.

There is now considerable experimental evidence to support the contribution of IL-17A to the pathogenesis of RA, varying from the linkage of Th17 cells with bone resorption [36] to observations of these same cells within and adjacent to synovial ELS [13]. However, a function directly attributable to IL-17A remains somewhat controversial, with other Th17 cell-derived cytokines also associated with the presence of synovial ELS [18]. Overall, we found \( IL17A \) gene expression in ~40% of synovia and that alone, \( IL17A \) gene expression was associated with larger lymphocytic aggregates in synovium. However, the combined expression of the \( IL17A \) and \( CD21L \) genes provided a clear distinction between different synovial subgroups, with \( IL17A^+/CD21L^+ \) synovia having significantly larger sized aggregates of lymphocytes that included CD20\(^-\) B-cells. Concomitantly there were no greater numbers of these B-cell containing aggregates, implicating a role for IL-17A in the stabilisation and/or expansion, but not necessarily the initiation of lymphoid aggregation. There is precedence for this in the murine system whereby continual IL-17A signalling is required to overcome a dissipating action of IL-23 and thereby maintain lymphoid aggregates [19, 37]. The combined data suggest that IL-17A signalling is important to the expansion and/or stability of B-cell and T-cell aggregates within rheumatoid synovia. The implication is that in synovia where IL-23 is also produced, low levels or a complete absence of IL-17A is likely to favour aggregate dissipation [19]. We observed greater \( IL23A \) gene expression in \( IL17A^+/CD21L^+ \) synovia that appears contrary to this process, but which is consistent with earlier reports [18]. However, this might reflect the threshold levels of IL-23 required to support Th17 cells and their production of IL-17A [38] as well as the
contribution from multiple other cytokines [34]. Consequently, dual roles for IL-23 in promoting IL-17A production and/or in dissipating lymphoid aggregates are predicted in rheumatoid synovia.

The temporal stability of GC+ ELS in inflamed synovium remains controversial [39–41]. Indications are that synovial lymphocyte aggregation is a dynamic process [42]. In our study, the availability of paired (and temporally separated) synovia was limited, thus restricting the ability to address this possibility. Separate synovia obtained from a single patient, 5 months apart, were classified into opposing IL17A/CD21L subgroups. In the paired synovia from this patient and from another two patients that also classified differently over time, gains in expression of IL17A and/or CD21L were the most notable feature. Whether this represents spontaneous behaviour of synovial aggregates, response (or lack thereof) to pharmacological treatments is unclear. Equally, whether IL17A+/CD21L+ and IL17A-/CD21L- synovia co-exist at the same time, within individual patients remains unknown.

Amongst those tested, the majority (~84%) within our patient cohort were ACPA+. Synovia from ACPA+ or ACPA- patients were not confined to a particular IL17A/CD21L synovial subgroup. Consequently, we were unable to replicate data that link greater synovial B cell infiltrates and lymphoid aggregates with ACPA positivity [43]. The comparatively smaller sample size, the higher percentage of synovia from ACPA+ patients within our cohort and longer disease duration of patients in our study potentially contribute to this anomaly.

While IL17A+/CD21L+ or IL17A-/CD21L- synovia are essentially polarised subgroups, the remaining two subgroups (i.e. IL17A-/CD21L- or IL17A+/CD21L-) that lack either IL17A or CD21L expression, display “intermediate” levels of lymphoid aggregation. However, it is unknown if these are transitional stages of synovial inflammation, progressing towards larger aggregates, or whether they represent a regression from these states. Together, the IL17A+/CD21L- and IL17A-/CD21L+ subgroups share comparable measures of IL23A expression, numbers and size of any lymphoid aggregates. However, by definition these are two molecularly distinct synovial subgroups. More information is required that deciphers the complexity of these synovia beyond expression of the IL17A and CD21L genes before they can be established as independent inflammatory stages.

Microarray analysis established distinct gene expression profiles for the more polarised IL17A+/CD21L- and IL17A-/CD21L+ synovia. These profiles indicate generally heightened immune activity in IL17A+/CD21L+ synovia including processes and pathways dominated by B-lymphocytes and their immune-mediated functions. Indeed, the profile for IL17A+/CD21L+ synovia is consistent with that previously described for “high inflammatory” synovia [44] and includes select genes (e.g. CD38, IGK, XBP1, MS4A1, CD19, SLAMF6, CXCL13) previously associated with a lymphoid synovial pathotype [1]. Amongst these genes there is growing evidence that CXCL13 directs B-lymphocyte accumulation and aggregation within synovium [1, 44, 45]. We also observed increased RGS13 expression in IL17A+/CD21L+ synovia, which is compatible with the mechanisms downstream of CXCL13-ligand and CXCR5-receptor interactions, driving this recruitment process [45, 46]. However, we have not had the opportunity to confirm promising indications [1] that circulating levels of CXCL13 provide a non-invasive indication of B-lymphocyte dominated synovial inflammation. In contrast, gene expression within IL17A-/CD21L- synovia suggests bone and cartilage morphogenesis or remodelling is a feature. The profile here, including genes such as DKK3, TNRSF11B/osteonecterin, WNT9B, and FGFR1, resembles that for “low inflammatory” synovia previously described [1, 44].

In summary, measures of IL17A and CD21L gene expression provide a molecular basis for the classification of rheumatoid synovia that in part accommodates histological differences. The lack of clinical correlation with the molecular data is consistent with published data
and it seems this classification is also unlikely to predict outcome in RA. However, the possibilities that $IL17A^+/CD21L^-$ synovia are more likely in ACPA$^+$ patients, or more easily predicted through measures of circulating CXCL13 require future investigation. Our data indicate that a distinct inflammatory process accompanies $IL17A$ and $CD21L$ co-expression. Clearly B-cells are involved and their prominence indicates that therapies targeting B-cells, such as rituximab, are likely to be more efficacious towards $IL17A^+/CD21L^-$ synovia. More detailed knowledge of the synovial inflammation associated with $IL17A^+$ and $CD21L^+$ expression should highlight additional targets and might offer the future prospect of selecting biological therapy based on the definition of these different types of joint synovial inflammation.

Author Contributions

Conceptualization: Lisa K. Stamp, John Highton, Paul A. Hessian.

Data curation: Kelly J. McKelvey, Paul A. Hessian.

Formal analysis: Kelly J. McKelvey, Terence C. Doyle, Paul A. Hessian.

Funding acquisition: Lisa K. Stamp, John Highton, Paul A. Hessian.

Investigation: Kelly J. McKelvey, Melanie J. Millier, Terence C. Doyle, Lisa K. Stamp, John Highton, Paul A. Hessian.

Methodology: Kelly J. McKelvey, Melanie J. Millier, Paul A. Hessian.

Project administration: Paul A. Hessian.

Supervision: Paul A. Hessian.

Validation: Kelly J. McKelvey, Melanie J. Millier, Terence C. Doyle, Lisa K. Stamp, Paul A. Hessian.

Writing – original draft: Kelly J. McKelvey, Melanie J. Millier, Lisa K. Stamp, John Highton, Paul A. Hessian.

Writing – review & editing: Kelly J. McKelvey.

References

1. Dennis G Holweg CTJ, Kummerfeld SK, Choy DF, Setiadi AF, Hackney JA, et al. Synovial phenotypes in rheumatoid arthritis correlate with response to biologic therapeutics. Arthritis Res Ther. 2014; 16: R90. https://doi.org/10.1186/ar4555 PMID: 25167216

2. Pitzalis C, Kelly S, Humby F. New learnings on the pathophysiology of RA from synovial biopsies. Curr Opin Rheumatol. 2013; 25: 334–344. https://doi.org/10.1097/BOR.0b013e32835fd8eb PMID: 23492740

3. Manzo A, Bombardieri M, Humby F, Pitzalis C. Secondary and ectopic lymphoid tissue responses in Rheumatoid Arthritis: from inflammation to autoimmunity and tissue damage/remodelling. Immunol Rev. 2010; 233: 267–285. https://doi.org/10.1111/j.0105-2896.2009.00861.x PMID: 20193005

4. Krautler NJ, Kana V, Kranich J, Tian Y, Perera D, Lemm D, et al. Follicular Dendritic Cells Emerge from Ubiquitous Perivascular Precursors. Cell. 2012; 150: 194–206. https://doi.org/10.1016/j.cell.2012.05.032 PMID: 22770220

5. Noort AR, van Zoest KP, van Baarsen LG, Maracle CX, Helder B, Papazian N, et al. Tertiary lymphoid structures in Rheumatoid Arthritis: NF-$\kappa$B-inducing kinase-positive endothelial cells as central players. Am J Pathol. 2015; 185: 1935–1943. https://doi.org/10.1016/j.ajpath.2015.03.012 PMID: 25963989

6. Finch DK, Ettinger R., Karnell JL., Herbst R., Sleeman MA. Effects of CXCL13 inhibition on lymphoid follicles in models of autoimmune disease. Eur J Clin Invest. 2013; 43: 501–509. https://doi.org/10.1111/ eci.12063 PMID: 23517338

7. Humby F, Bombardieri M, Manzo A, Kelly S, Kirkham B, Spencer J, et al. Ectopic lymphoid structures support ongoing production of class-switched autoantibodies in rheumatoid synovium. PLoS Med. 2009; 6: e1.
8. Liu YJ, de Bouteiller O, Parham CL, Grouard G, Djossou O, de Saint-Vis B, et al. Follicular dendritic cells specifically express the long CR2/CD21 isoform. J Exp Med. 1997; 185: 165–170. PMID: 8996252

9. Scheel T, Gursche A, Zacher J, Haupi T, Berek C. V-region analysis of locally defined synovial B and plasma cells reveals selected B cell expansion and accumulation of plasma cell clones in rheumatoid arthritis. Arthritis Rheum. 2011; 63: 63–71. https://doi.org/10.1002/art.27767 PMID: 20882667

10. Takemura S, Braun A, Crowson C, Kurtin PJ, Cofield RH, O’Fallon WM, et al. Lymphoid neogenesis in rheumatoid synovitis. J Immunol. 2001; 167: 1072–1080. PMID: 11441118

11. Randen I, Mellbye OJ, Forre O, Natvig JB. The identification of germinal centres and follicular dendritic cell networks in rheumatoid synovial tissue. Scand J Immunol. 1995; 41: 481–486. PMID: 7725067

12. Kirkham BW, Lassere MN, Edmonds JP, Juhasz KM, Bird PA, Lee CS, Shnier R, Portek IJ. Synovial membrane cytokine expression is predictive of joint damage progression in rheumatoid arthritis: a two-year prospective study (the DAMAGE study cohort). Arthritis Rheum. 2006; 54: 1122–1131. https://doi.org/10.1002/art.21749 PMID: 16572447

13. Chabaud M, Durand JM, Buchs N, Fossiez F, Page G, Frappart L, et al. Human interleukin-17: A T-cell derived proinflammatory cytokine produced by the rheumatoid synovium. Arthritis Rheum. 1999; 42: 963–970. https://doi.org/10.1002/1529-0131(199905)42:5<963::AID-ANR15>3.0.CO;2-E PMID: 10323452

14. Moran EM, Mullan R, McCormick J, Connolly M, Sullivan O, Fitzgerald O, et al. Human rheumatoid arthritis tissue production of IL-17A drives matrix and cartilage degradation: synergy with tumour necrosis factor-alpha, Oncostatin M and response to biologic therapies. Arthritis Res Ther. 2009; 11: R113. https://doi.org/10.1186/ar2772 PMID: 19627579

15. Koshy PJ, Henderson N, Logan C, Life PF, Cawston TE, Rowan AD. Interleukin-17 induces cartilage breakdown: novel synergistic effects in combination with proinflammatory cytokines. Ann Rheum Dis. 2002; 61: 704–713. https://doi.org/10.1136/ard.61.8.704 PMID: 12117676

16. Wei M, Duan D. Efficacy and safety of monoclonal antibodies targeting interleukin-17 pathway for rheumatoid arthritis. Arthritis Rheum. 2011; 63: 63–71. https://doi.org/10.1002/art.27767 PMID: 20882667

17. Stamp LK, Easson A, Pettersson L, Highton J, Hessian PA. Monocyte Derived Interleukin (IL)-23 is an Important Determinant of synovial IL-17A expression in Rheumatoid Arthritis. J. Rheumatol. 2009; 36: 2403–2408. https://doi.org/10.3899/jrheum.081304 PMID: 19797506

18. Canete JD, Celis R, Yeremenko N, Sanmarti R, van Duivenvoorde L, Ramirez J, et al. Ectopic lymphoid neogenesis is strongly associated with activation of the IL-23 pathway in rheumatoid arthritis. Arthritis Res Ther. 2015; 17: 173. https://doi.org/10.1186/s13075-015-0688-0 PMID: 26156866

19. Hsu HC, Yang P, Wang J, Wu Q, Myers R, Chen J, et al. Interleukin 17-producing T helper cells and interleukin 17 orchestrate autoreactive germinal center development in autoimmune BXD2 mice. Nat Immunol. 2008; 9: 166–175. https://doi.org/10.1038/nii152 PMID: 18157131

20. Kishi Y, Kondo T, Xiaos, Yosel N, Gaublomme J, Wu C, et al. Protein C receptor (PROC) is a negative regulator of Th17 pathogenicity. J Exp Med. 2016; 213: 2489–2501. https://doi.org/10.1084/jem.201511118 PMID: 27670590

21. Nylander AN, Ponath GD, Ayisxa P-P, Mubarak M, Tomayko M, Kuchroo VK, et al. Podoplanin is a negative regulator of Th17 inflammation. J Clin Invest Insight. 2017; 2: e92321. https://doi.org/10.1172/jci.insight.92321 PMID: 28878118

22. Gaublomme JT, Yosel N, Lee Y, Gertner RS, Yang LV, Wu C, et al. Single cell genomics uncovers critical regulators of Th17 cell pathogenesis. Cell. 2015; 163: 1400–1412. https://doi.org/10.1016/j.cell.2015.11.009 PMID: 26607794

23. Wang C, Yosel N, Gaublomme J, Wu C, Lee Y, Clish CB, et al. CD5/AIM regulates lipid biosynthesis and restrains Th17 cell pathogenicity. Cell. 2015; 163: 1413–1427. https://doi.org/10.1016/j.cell.2015.10.068 PMID: 26607793

24. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988; 31: 315–324. PMID: 33587996

25. Millier MJ, Stamp LK, Hessian PA. Digital-PCR for gene expression: impact from inherent tissue RNA degradation. Sci Rep. 2017; 7: 943–947.

26. Yanni G, Whelan A, Felchery C, Bresnihan B. Analysis of cell populations in rheumatoid arthritis synovial tissues. Semin Arthritis Rheum. 1992; 21: 393–399. PMID: 1626285

27. Irizarry RA, Hobbs B, Collins F, Bezazer-Bray YD, Antonellis KJ, Scherf U, et al. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics. 2003; 4: 249–264. https://doi.org/10.1093/biostatistics/4.2.249 PMID: 12925520
28. Wettenhall JM, Simpson KM, Satterley K, Smyth GK. AffyLmGUI: a graphical user interface for linear modelling of single channel microarray data. Bioinformatics. 2006; 22: 897–899. https://doi.org/10.1093/bioinformatics/btl025 PMID: 16455752

29. Eisen MB, Spellman PT, Brown PO, Botstein D. Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci. 1998; 95: 14863–14868. PMID: 9843981

30. Thomas PD, Campbell MJ, Keyarawi A, Mi H, Karlab B, Daverman R. PANTHER: A Library of Protein Families and Subfamilies Indexed by Function. Genome Res. 2003; 13: 2129–2141. https://doi.org/10.1101/gr.772403 PMID: 12952881

31. Cho R.J. and Campbell M.J., Transcrip tion, genomes, function. Trends Genet. 2000; 16: 409–415. PMID: 10973070

32. Jones GW, Hill DG, Jones SA. Understanding immune cells in tertiary lymphoid organ development: It is all starting to come together. Front Immunol. 2016; 7: 401. https://doi.org/10.3389/fimmu.2016.00401 PMID: 27752256

33. Van der Heijde DM, van Riel PL, Nuver-Zwart IH, Gribnau FW, vad de Putte LB. Effects of hydroxychloroquine and sulphasalazine on progression of joint damage in rheumatoid arthritis. Lancet. 1989; 1: 1036–1038. PMID: 2565997

34. Zhang X, Jin J, Peng X, Ramgolam VS, Markovic-Plese S. Simvas tin inhibits IL-17 secretion by targeting multiple IL-17-regulato ry cytokines and by inhibiting the expression of IL-17 transcription factor RORC in CD4+ lymphocytes. J Immunol. 2008; 180: 6988–6996. PMID: 18453621

35. Bom bardieri M., Lewis M., Pitzalis C. Ectopic lymphoid neogenesis in rheumatic autoimmune diseases. Nat Rev Rheumatol. 2017; 1: 141–154.

36. Sato K, Suematsu A, Okamoto K, Yamaguchi A, Morishita Y, Kadono Y, et al. Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction. J Exp Med. 2006; 203: 2673–2682. https://doi.org/10.1084/jem.20061775 PMID: 17088434

37. Ding Y., Li J., Wu Q., Yang P., Luo B., Xie S., et al. IL-1RA is essential for optimal localisation of follicular Th cells in the germinal centre light zone to promote autoantibody-producing B cells. J Immunol. 2013; 191: 1614–1624. https://doi.org/10.4049/jimmunol.1300479 PMID: 23858031

38. Yago T, Nanke Y, Kawamoto M, Furuya T, Kobashigawa T, Kamatani N, et al. IL-23 induces human osteoclastogenesis via IL-17 in vitro, and anti-IL-23 antibody attenuates collagen-induced arthritis in rats. Arthritis Res Ther. 2007; 9: R996 https://doi.org/10.1186/ar2297 PMID: 17888176

39. Manzo A, Paolletti S, Carulli M, Blades MC, Barone F, Yanni G, et al. Systematic microanatomical analysis of CXCL13 and CCL21 in situ production and progressive lymphoid organisation in rheumatoid synovitis. Eur. J. Immunol. 2005; 35: 1347–1359. https://doi.org/10.1002/eji.200425830 PMID: 15832291

40. Weyand C, Gorozny J. Ectopic germinal centre formation in rheumatoid synovitis. Ann N J Acad Sci. 2003; 987: 140–149.

41. Cantaert T, Kolln J, Timmer T, van der Pouw Kraan T, Vandooren B, Thurlings RM, et al. Lymphocyte autoimmunity in rheumatoid synovitis is independent of ectopic lymphoid neogenesis. J Immunol. 2008; 181:785–794. PMID: 18566445

42. Van de Sande MG, Thurling C, van de Pouw Kraan TCT, Tak PP, Verweij CL. Synovial tissue heterogeneity in rheumatoid arthritis in relation to disease activity and biomarkers in peripheral blood. Arth Rheum. 2017; 69: 2114–2123.

43. Orr C, Najm A, Biniecka M, McGarty T, Ng C, Young F, et al. Synovial phenotype and anti-citrullinated peptide antibodies in rheumatoid arthritis patients. Arth Rheum. 2017; 69: 2114–2123.

44. Armas-Gonzalez E, Domínguez-Luis MJ, Diaz-Martin A, Arce-Franco M, Castro-Hernandez J, Danelon G, et al. Role of CXCL13 and CCL20 in the recruitment of B cells to inflammatory foci in chronic arthritis. Arthritis Res Ther. 2018; 20 114. https://doi.org/10.1186/s13075-018-1611-22

45. Shi GX, Harrison K, Wilson GL, Moratz C, Kehrl JH. RGS13 regulates germinal center B lymphocytes responsiveness to CXC chemokine ligand (CXCL)12 and CXCL13. J. Immunol. J. Immunol. 2002; 169: 2507–2515. PMID: 12193720